It was recently completed a clinical trial with 25 IBS-D patients involved, which allowed the evaluation of the efficacy of Colicron treatment in improving the symptoms and the clinical picture in these subjects.
The trial expected the administration of Colicron for 8 weeks, 2 caps per day. At the beginning, after 4 weeks and then at the end of the treatment, the plasmatic level of zonulin were evaluated, together with the symptoms level.
The dosage of the zonulin levels allows the evaluation of the intestinal barrier integrity and intestinal permeability. The protein zonulin modulates the tight junction between the enterocytes, the cell constituting the intestinal wall. It is responsible for the weakness of the tight junction, consequently for the increased intestinal permeability. The increased intestinal permeability is related to chronic inflammatory diseases, since the transit of unwanted molecules and compounds through the intestinal epithelium causes the activation of a strong inflammatory response.
Colicron allows the reduction of the plasmatic zonulin levels, already after 4 weeks of treatment, with a further decreasing at the end of the 8-weeks-treatment.

The improving of the clinical parameters is associated with less intense symptoms, indeed 68% of the patients record the improvement of pain and 64% of them declare the improvement of bloating; these symptoms are typical in the IBS-D condition.
This pilot study demonstrates that Colicron can reduce the intestinal permeability, improving the symptoms associated to IBS.